Interpretation of Key Points in 2024 Chinese Expert Consensus on <i>EGFR</i> Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer

JIN Xuanhong; ZHOU Fei

doi:10.3971/j.issn.1000-8578.2025.25.0120

Cancer Research on Prevention and Treatment > 2025 > 52(6): 520-526. > DOI: 10.3971/j.issn.1000-8578.2025.25.0120

JIN Xuanhong, ZHOU Fei. Interpretation of Key Points in 2024 Chinese Expert Consensus on EGFR Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2025, 52(6): 520-526. DOI: 10.3971/j.issn.1000-8578.2025.25.0120

Citation:

PDF (1656 KB)

Interpretation of Key Points in 2024 Chinese Expert Consensus on EGFR Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer

JIN Xuanhong^1, ,,
ZHOU Fei^2, , ,

1.
Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou 310016, China
2.
Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China

Funding:

National Natural Science Foundation of China (No. 81703020); Natural Science Foundation of Shanghai (No. 23ZR1453500)

undefined

More Information

Corresponding author:
ZHOU Fei, E-mail: fei.zhou@tongji.edu.cn
Received Date: February 23, 2025
Revised Date: April 02, 2025
Accepted Date: April 07, 2025
Available Online: April 13, 2025

Graphical Abstract

Abstract

Abstract

The Chinese Society of Clinical Oncology (CSCO) NSCLC Expert Committee has updated the 2023 Chinese expert consensus in light of the growing understanding of epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC) and the emergence of new clinical data from targeted therapies. Based on the latest domestic and international literature, clinical evidence, and expert experience, the “Chinese Expert Consensus on the Standardized Diagnosis and Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2024 Edition)” introduces refinements in the diagnostic and upcoming therapeutic strategies for this rare mutation. This article also highlights the key updates and recommendations in the 2024 consensus compared to the 2023 version as well as outlines future directions to optimize clinical practices and improve patient outcomes.
- Non-small cell lung cancer,
- EGFR exon 20 insertion,
- Targeted therapy strategies

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (37)

References

[1]	Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. doi: 10.1016/j.jncc.2024.01.006
[2]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. doi: 10.3322/caac.21708
[3]	Yatabe Y, Kerr KM, Utomo A, et al. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey[J]. J Thorac Oncol, 2015, 10(3): 438-445. doi: 10.1097/JTO.0000000000000422
[4]	Burnett H, Emich H, Carroll C, et al. Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review[J]. PLoS One, 2021, 16(3): e0247620. doi: 10.1371/journal.pone.0247620
[5]	Ou SI, Hong JL, Christopoulos P, et al. Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC[J]. J Thorac Oncol, 2023, 18(6): 744-754. doi: 10.1016/j.jtho.2023.01.086
[6]	Robichaux JP, Le X, Vijayan RSK, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC[J]. Nature, 2021, 597(7878): 732-737. doi: 10.1038/s41586-021-03898-1
[7]	Bai Q, Wang J, Zhou X. EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies[J]. Cancer Treat Rev, 2023, 120: 102605. doi: 10.1016/j.ctrv.2023.102605
[8]	中国临床肿瘤学会非小细胞肺癌专家委员会. EGFR 20外显子插入突变非小细胞肺癌规范化诊疗中国专家共识(2024版)[J]. 中国肺癌杂志, 2024, 27(7): 485-494. [Chinese Society of Clinical Oncology Non-small Cell Lung Cancer Committee. Chinese expert consensus on the standardized diagnosis and treatment of non-small cell lung cancer with EGFR 20 exon insertion mutation (2024 edition)[J]. Zhongguo Fei Ai Za Zhi, 2024, 27(7): 485-494.] doi: 10.3779/j.issn.1009-3419.2024.102.27 Chinese Society of Clinical Oncology Non-small Cell Lung Cancer Committee. Chinese expert consensus on the standardized diagnosis and treatment of non-small cell lung cancer with EGFR 20 exon insertion mutation (2024 edition)[J]. Zhongguo Fei Ai Za Zhi, 2024, 27(7): 485-494. doi: 10.3779/j.issn.1009-3419.2024.102.27
[9]	Feng Y, Feng G, Lu X, et al. Exploratory analysis of introducing next-generation sequencing-based method to treatment-naive lung cancer patients[J]. J Thorac Dis, 2018, 10(10): 5904-5912. doi: 10.21037/jtd.2018.09.108
[10]	Zhou C, Li B, Fang J, et al. 586P Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment[J]. Ann Oncol, 2023, 34(Suppl_4): S1699.
[11]	Lanman RB, Mortimer SA, Zill OA, et al. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA[J]. PLoS One, 2015, 10(10): e0140712. doi: 10.1371/journal.pone.0140712
[12]	Pennell NA, Arcila ME, Gandara DR, et al. Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices[J]. Am Soc Clin Oncol Educ Book, 2019, 39: 531-542.
[13]	中国抗癌协会肿瘤病理专业委员会分子病理协作组, 中国医师协会肿瘤多学科诊疗专业委员会. 非小细胞肺癌表皮生长因子受体20号外显子插入突变检测临床实践中国专家共识(2024版)[J]. 中华肿瘤杂志, 2024, 46(3): 179-188. [Molecular Pathology Collaboration Group of the Tumor Pathology Professional Committee of the Chinese Anti Cancer Association, Multidisciplinary Diagnosis and Treatment Professional Committee of the Chinese. Expert consensus on clinical practice of EGFR exon 20 insertion detection in non-small cell lung cancer in China (2024 edition)[J]. Zhonghua Zhong Liu Za Zhi, 2024, 46(3): 179-188.] doi: 10.3760/cma.j.cn112152-20230905-00125 Molecular Pathology Collaboration Group of the Tumor Pathology Professional Committee of the Chinese Anti Cancer Association, Multidisciplinary Diagnosis and Treatment Professional Committee of the Chinese. Expert consensus on clinical practice of EGFR exon 20 insertion detection in non-small cell lung cancer in China (2024 edition)[J]. Zhonghua Zhong Liu Za Zhi, 2024, 46(3): 179-188. doi: 10.3760/cma.j.cn112152-20230905-00125
[14]	Neal J, Li Y, Yu Z, et al. Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA)[J]. J Clin Oncol, 2023, 41(Suppl_16): 9082.
[15]	Jahangiri L, Hurst T. Assessing the Concordance of Genomic Alterations between Circulating-Free DNA and Tumour Tissue in Cancer Patients[J]. Cancers (Basel), 2019, 11(12): 1938. doi: 10.3390/cancers11121938
[16]	Passaro A, Leighl N, Blackhall F, et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer[J]. Ann Oncol, 2022, 33(5): 466-487. doi: 10.1016/j.annonc.2022.02.003
[17]	Ou SI, Lin HM, Hong JL, et al. Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations[J]. JTO Clin Res Rep, 2023, 4(10): 100558.
[18]	Yang G, Li J, Xu H, et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study[J]. Lung Cancer, 2020, 145: 186-194. doi: 10.1016/j.lungcan.2020.03.014
[19]	Zwierenga F, Van Veggel B, Hendriks LEL, et al. High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial[J]. Lung Cancer, 2022, 170: 133-140. doi: 10.1016/j.lungcan.2022.06.012
[20]	Zhou C, Tang KJ, Cho BC, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions[J]. N Engl J Med, 2023, 389(22): 2039-2051. doi: 10.1056/NEJMoa2306441
[21]	Jänne PA, Wang B, Cho BC, et al. 5070-EXCLAIM-2: Phase 3 trial of first-line mobocertinib versus platinum-based chemotherapy in patients with EGFR exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC[EB/OL]. ESMO Asia 2023, [2023-12-02]. https://oncologypro.esmo.org/meeting-resources/esmo-asia-congress-2023/exclaim-2-phase-iii-trial-of-first-line-1l-mobocertinib-versus-platinum-based-chemotherapy-in-patients-pts-with-epidermal-growth-factor-recept.
[22]	Jänne PA, Wang BC, Cho BC, et al. First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase Ⅲ EXCLAIM-2 Trial[J]. J Clin Oncol, 2025: Jco2401269. Online ahead of print.
[23]	Yang JC, Wang M, Luo Y, et al. 1325P-Sunvozertinib as first-line treatment in NSCLC patients with EGFR exon20 insertion mutations[EB/OL]. ESMO 2023, [2023-10-21]. https://oncologypro.esmo.org/meeting-resources/esmo-congress-2023/sunvozertinib-as-first-line-treatment-in-nsclc-patients-with-egfr-exon20-insertion-mutations.
[24]	A study of DZD9008 versus platinum-based doublet chemotherapy in local advanced or metastatic non-small cell lung cancer (WU-KONG28)[EB/OL]. [2025-03-25]. https://clinicaltrials.gov/study/NCT05668988?term=NCT05668988&rank=1.
[25]	YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations[EB/OL]. [2023-04-05]. https://clinicaltrials.gov/study/NCT05767892?limit=10&term=NCT05767892&rank=1.
[26]	Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)[EB/OL]. [2025-03-25]. https://clinicaltrials.gov/study/NCT05607550?limit=10&term=NCT05607550&rank=1.
[27]	REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (REZILIENT3)[EB/OL]. [2025-03-25]. https://clinicaltrials.gov/study/NCT05973773?limit=10&term=NCT05973773&rank=1.
[28]	JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations[EB/OL]. [2024-04-23]. https://clinicaltrials.gov/study/NCT06380348?limit=10&term=NCT06380348&rank=1.
[29]	Wang M, Fan Y, Sun M, et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial[J]. Lancet Respir Med, 2024, 12(3): 217-224. doi: 10.1016/S2213-2600(23)00379-X
[30]	Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase Ⅰ Study[J]. J Clin Oncol, 2021, 39(30): 3391-3402. doi: 10.1200/JCO.21.00662
[31]	Piotrowska Z, Tan DS, Smit EF, et al. Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions[J]. J Clin Oncol, 2023, 41(26): 4218-4225. doi: 10.1200/JCO.23.00152
[32]	Han BH, Zhou CZ, Zheng W, et al. OA03.04 A phase 1b study of furmonertinib, an oral, brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR exon 20 insertions[J]. J Thorac Oncol, 2023, 18(11 Suppl): S49.
[33]	Zhao S, Zhuang W, Han B, et al. Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer[J]. Nat Commun, 2023, 14(1): 3468. doi: 10.1038/s41467-023-39139-4
[34]	Nguyen D, Shum E, Baik CS, et al. Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions[J]. J Clin Oncol, 2023, 41(Suppl_16): 9064. doi: 10.1200/JCO.2023.41.16_suppl.9064
[35]	A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer (FWD1509)[EB/OL]. [2022-07-26]. https://clinicaltrials.gov/study/NCT05068024?limit=10&term=%20NCT05068024&rank=1.
[36]	BEBT-109在EGFR 20外显子插入突变局部晚期或转移性非小细胞肺癌患者中的有效性和安全性的Ⅱ期临床试验[EB/OL]. [2021-12-31]. http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml. [Phase Ⅱ clinical trial of the efficacy and safety of BEBT-109 in patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutation[EB/OL]. [2021-12-31]. http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml.] Phase Ⅱ clinical trial of the efficacy and safety of BEBT-109 in patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutation[EB/OL]. [2021-12-31]. http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml.
[37]	Yang JJ, Wu YL, Huang MJ, et al. Interim results of a first-in-human, dose escalation and expansion study of PLB-1004, an irreversible inhibitor of exon 20 insertion mutations in patients with non-small cell lung cancer[J]. Cancer Res, 2023, 83(8_Suppl): CT102.

Cited By

Get Citation

PDF

XML

Article views (1488) PDF downloads (460)

Turn off MathJax

Article Contents

Abstract

References

Interpretation of Key Points in 2024 Chinese Expert Consensus on EGFR Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer

Abstract

References

Catalog

Download Center

Links

Contact Us

Interpretation of Key Points in 2024 Chinese Expert Consensus on EGFR Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer

Abstract

References

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content